SCHEMBL25215967

SCHEMBL25215967

O=C(O)N[C@H](Cc1ccc(Cl)cc1)C(=O)Nc1cc(-c2ccncc2)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 4/20 0.46
▸ ROCK2 O75116 2/20 0.44
▸ ROCK1 Q13464 2/20 0.44
▸ PRKACA P17612 1/20 0.44
▸ RPS6KB1 P23443 1/20 0.44
▸ IRAK1 P51617 1/20 0.44
▸ PRKX P51817 1/20 0.44
▸ LIMK1 P53667 1/20 0.44
▸ PRKG2 Q13237 1/20 0.44
▸ PRKG1 Q13976 1/20 0.44
▸ PKN2 Q16513 1/20 0.44
▸ HIPK4 Q8NE63 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ CSNK1G1 Q9HCP0 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ GPR142 Q7Z601 5/20 0.43
▸ TP53 P04637 1/20 0.41
▸ TACR3 P29371 1/20 0.41
▸ CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25254663 1.00 MME (0.46) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL25254658 1.00 MME (0.46) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL2685242 0.92 MME (0.50) MMEROCK2ROCK1PRKACAIRAK1
SCHEMBL24867024 0.88 GPR142 (0.44) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL30443710 0.86 HDAC8 (0.46) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL26713282 0.86 HDAC8 (0.46) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL24867453 0.85 MME (0.47) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL25221535 0.84 GPR142 (0.60) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL25256782 0.84 GPR142 (0.60) MMEROCK2ROCK1PRKACARPS6KB1
SCHEMBL29331221 0.84 GPR142 (0.45) MMEROCK2ROCK1PRKACARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-04-30 — — US disclosed
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2024-04-11 — — US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 — — US disclosed
EP-4192828-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2023-06-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 MME 3110/4885ROCK2 2248/4885ROCK1 2158/4885
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 MME 3110/4885ROCK2 2248/4885ROCK1 2158/4885
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 MME 3110/4885ROCK2 2248/4885ROCK1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback